152 related articles for article (PubMed ID: 35678337)
21. Adjuvant therapy for high-risk gastrointestinal stromal tumour: considerations for optimal management.
Joensuu H
Drugs; 2012 Oct; 72(15):1953-63. PubMed ID: 22994537
[TBL] [Abstract][Full Text] [Related]
22. Gastrointestinal stromal tumor: 15-years' experience in a single center.
Wang M; Xu J; Zhang Y; Tu L; Qiu WQ; Wang CJ; Shen YY; Liu Q; Cao H
BMC Surg; 2014 Nov; 14():93. PubMed ID: 25403624
[TBL] [Abstract][Full Text] [Related]
23. [Clinical analysis of 156 patients with gastrointestinal stromal tumors receiving imatinib therapy].
Zhang L; Cai M; Deng J; Wang X; Wang B; Liu N; Pan Y; Zhang R; Cui Q; Liang H
Zhonghua Wei Chang Wai Ke Za Zhi; 2014 Apr; 17(4):331-4. PubMed ID: 24760639
[TBL] [Abstract][Full Text] [Related]
24. A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome.
Zhu J; Yang Y; Zhou L; Jiang M; Hou M
BMC Cancer; 2010 May; 10():199. PubMed ID: 20465813
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant treatment of GIST: patient selection and treatment strategies.
Joensuu H
Nat Rev Clin Oncol; 2012 Apr; 9(6):351-8. PubMed ID: 22525709
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.
Dematteo RP; Ballman KV; Antonescu CR; Maki RG; Pisters PW; Demetri GD; Blackstein ME; Blanke CD; von Mehren M; Brennan MF; Patel S; McCarter MD; Polikoff JA; Tan BR; Owzar K;
Lancet; 2009 Mar; 373(9669):1097-104. PubMed ID: 19303137
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial.
Majer IM; Gelderblom H; van den Hout WB; Gray E; Verheggen BG
J Med Econ; 2013 Sep; 16(9):1106-19. PubMed ID: 23808902
[TBL] [Abstract][Full Text] [Related]
28. Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence.
McCarter MD; Antonescu CR; Ballman KV; Maki RG; Pisters PW; Demetri GD; Blanke CD; von Mehren M; Brennan MF; McCall L; Ota DM; DeMatteo RP;
J Am Coll Surg; 2012 Jul; 215(1):53-9; discussion 59-60. PubMed ID: 22726733
[TBL] [Abstract][Full Text] [Related]
29. Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - the impact of tumour rupture on patient outcomes.
Rutkowski P; Bylina E; Wozniak A; Nowecki ZI; Osuch C; Matlok M; Switaj T; Michej W; Wroński M; Głuszek S; Kroc J; Nasierowska-Guttmejer A; Joensuu H
Eur J Surg Oncol; 2011 Oct; 37(10):890-6. PubMed ID: 21737227
[TBL] [Abstract][Full Text] [Related]
30. Retrospective analysis of 85 cases of intermediate-risk gastrointestinal stromal tumor.
Fu Y; Hao H; Guo L; Yang G; Zhang X
Oncotarget; 2017 Feb; 8(6):10136-10144. PubMed ID: 28052037
[TBL] [Abstract][Full Text] [Related]
31. Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up.
Joensuu H; Eriksson M; Sundby Hall K; Reichardt A; Hermes B; Schütte J; Cameron S; Hohenberger P; Jost PJ; Al-Batran SE; Lindner LH; Bauer S; Wardelmann E; Nilsson B; Kallio R; Jaakkola P; Junnila J; Alvegård T; Reichardt P
JAMA Oncol; 2020 Aug; 6(8):1241-1246. PubMed ID: 32469385
[TBL] [Abstract][Full Text] [Related]
32. Follow-up strategies for patients with gastrointestinal stromal tumour treated with or without adjuvant imatinib after surgery.
Joensuu H; Martin-Broto J; Nishida T; Reichardt P; Schöffski P; Maki RG
Eur J Cancer; 2015 Aug; 51(12):1611-7. PubMed ID: 26022432
[TBL] [Abstract][Full Text] [Related]
33. Postoperative imatinib in patients with intermediate risk gastrointestinal stromal tumor.
Wu X; Li J; Xu W; Gao J; Li Y; Shen L
Future Oncol; 2018 Jul; 14(17):1721-1729. PubMed ID: 29969914
[TBL] [Abstract][Full Text] [Related]
34. The efficacy of adjuvant imatinib therapy in improving the prognosis of patients with colorectal gastrointestinal stromal tumours.
Li Y; Meng X
Ann R Coll Surg Engl; 2015 Apr; 97(3):215-20. PubMed ID: 26263807
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of Ki67 index in gastrointestinal stromal tumors.
Zhao WY; Xu J; Wang M; Zhang ZZ; Tu L; Wang CJ; Lin TL; Shen YY; Liu Q; Cao H
Int J Clin Exp Pathol; 2014; 7(5):2298-304. PubMed ID: 24966939
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant imatinib treatment after R0 resection for patients with high-risk gastrointestinal stromal tumors: a median follow-up of 44 months.
Jiang WZ; Guan GX; Lu HS; Yang YH; Kang DY; Huang HG
J Surg Oncol; 2011 Dec; 104(7):760-4. PubMed ID: 21713778
[TBL] [Abstract][Full Text] [Related]
37. Imatinib therapy after resection of high-risk gastrointestinal stromal tumors in Chinese patients: a median follow-up of 48 months.
Lei C; Zhao B; Wang Q; Ge L; Wang H
J BUON; 2018; 23(2):460-467. PubMed ID: 29745093
[TBL] [Abstract][Full Text] [Related]
38. Surgical outcomes of gastrointestinal stromal tumors of the stomach: a single unit experience in the era of targeted drug therapy.
Huang H; Liang H; Zhan ZL; Li H; Ren XB; Hao XS
Med Oncol; 2012 Jun; 29(2):941-7. PubMed ID: 21390518
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathologic analysis of gastrointestinal stromal tumors in duodenum and small intestine.
Han IW; Jang JY; Lee KB; Kang MJ; Kwon W; Park JW; Chang YR; Lee HJ; Park KJ; Kim SW
World J Surg; 2015 Apr; 39(4):1026-33. PubMed ID: 25270345
[TBL] [Abstract][Full Text] [Related]
40. Management of gastrointestinal stromal tumors: looking beyond the knife. An update on the role of adjuvant and neoadjuvant imatinib therapy.
Pandey R; Kochar R
J Gastrointest Cancer; 2012 Dec; 43(4):547-52. PubMed ID: 22847491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
